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EC: European Commission  
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[Note: Throughout this thesis figures and statistics are expressed in the format 
“YYYY/YY” (e.g. 2013/14) for financial year data—running form 1 April to 31 March—
and “YYYY” (e.g. 2014) for calendar year data.] 
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1 Introduction 
 
Providing healthcare to citizens may be considered one of the hallmarks of a welfare 
state. The World Health Organization (WHO) even regards it as a “fundamental right of 
every human being” (WHO, 2015). Unfortunately, many countries are struggling and 
especially in the European Union the costs of providing public healthcare seem overly 
high, considering the recent economic events and turmoil. The situation is exacerbated 
by the severe pressures brought on by factors such as an aging population and influx 
of lifestyle conditions in much of the western world.  
 
Simultaneously many technology industries are booming and major advances are 
constantly made in various areas. One of these is the health technology industry, 
which in Finland seems to do exceptionally well. This thesis intends to assist a health 
technology start-up, Finnish medical device manufacturer Medieta Oy, in bringing their 
innovation to new markets where it will hopefully help ensure that healthcare is 
delivered not only efficiently, but safely and effectively, and bring cutting-edge 
technology to a field that could immensely benefit from it.  
 
The present research aims at providing a comprehensive overview of the public 
healthcare market in England in the context of it being a potential new market for 
Medieta. The goal is to provide an understanding of the system and its components, 
determine if there would be demand for the type of product Medieta is offering, and 
identify potential requirements that might act as barriers to entry. This is accomplished 
by conducting reviews on significant demographic factors, the National Health Service 
(NHS) of England, as well as the regulation and monitoring of medical devices and the 
NHS. Finally, the key findings are summed up in a discussion and conclusions are 
drawn.  
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2 Background to the study 
 
2.1 Commissioner of the thesis and selection of topic 
 
The commissioner of the present thesis is Medieta Oy, a Finnish medical device 
manufacturer. Medieta’s product is a wearable, wireless bracelet for monitoring vital 
signs with accompanying software to alert medical staff of any concerning changes—in 
other words, a system for early risk recognition in patients under medical supervision. 
Due to data being transmitted wirelessly, the device may be used to monitor patients 
after they have been discharged as well, in addition to having possible applications in 
various types of units such as care homes for the elderly. The device is being currently 
tested in selected Finnish hospitals in order to attain clinical data. While the product is 
not on the market yet, a CE marking and ISO certification have been obtained for the 
software already.  
 
The idea for the thesis stemmed from discussions with the CEO of Medieta, Jouni 
Ruoppa, who expressed interest in the possibility of taking the product abroad to other 
markets and receiving a study on a market of interest. Europe and the United Kingdom 
emerged as viable options, so, in order to limit complexity, England was selected as 
the geographical area. Originally the thesis was to consider the entire healthcare 
system, along with relevant external factors, but it soon became evident, the focus 
should be narrowed down in order to avoid a superficial end product lacking proper 
detail. Thus, the public health sector, which is vast and accounts for the majority of all 
healthcare expenditure, was selected as the core topic. It was also decided that the 
thesis would focus on aspects most relevant to a medical device manufacturer, while 
still offering a comprehensive overview of the public health system. All proprietary 
information—including product specifics and financial data—were to be excluded. 
 
2.2 Medieta’s device in the EU market 
 
The European Commission (EC) defines a medical device in the Council Directive 
93/42/EEC on Medical Devices (MDD), as follows 
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‘medical device’ means any instrument, apparatus, appliance, software, material or 
other article, whether used alone or in combination, including the software 
intended by its manufacturer to be used specifically for diagnostic and/or 
therapeutic purposes and necessary for its proper application, intended by the 
manufacturer to be used for human beings for the purpose of:  
 
• diagnosis, prevention, monitoring, treatment or alleviation of disease,  
• diagnosis, monitoring, treatment, alleviation of or compensation for an 
injury or handicap,  
• investigation, replacement or modification of the anatomy or of a 
physiological process,  
• control of conception,  
 
and which does not achieve its principal intended action in or on the human body 
by pharmacological, immunological or metabolic means, but which may be assisted 
in its function by such means; (Council Directive 93/42/EEC) 
 
The EC additionally divides medical devices into four classes—I, IIa, IIb, and III—
separated into these groups “essentially for the purpose of conformity assessment 
procedures” (Council Directive 93/42/EEC). Since Medieta’s product is a system 
composed of a mobile monitoring and diagnostic device along with software for 
monitoring vital signs, it is considered class IIa-IIb, depending on the functions made 
available, and defined as an “active device” according to rule 10 (Council Directive 
93/42/EEC: 10–11, 42).  
 
Considering Medieta’s product is a mobile, sensory device worn on the wrist with 
compatible software for data management, it is necessary to emphasise the distinction 
between such a system intended for clinical use in the healthcare system and 
numerous wellness and fitness wearables with compatible software available freely on 
the market for consumers. The latter include especially smartwatches, activity 
bracelets and heart rate monitors (e.g. Apple Watch, Fitbit, Jawbone UP, and Nike 
Dualband) combined with computer programmes or phone “apps”, which do not have 
the same stringent requirements and standards as medical devices, nor are they 
intended for diagnostic purposes or use in medical establishments.  
 
2.3 Overview of the medical device industry in Europe  
 
Medical devices and medical technology make up a sizeable, growing industry in 
Europe. The key characteristics and latest figures on the European medical technology 
industry—presented by MedTech Europe (2014), an alliance of European medical 
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technology associations device industry consisting of Eucomed and European 
Diagnostic Manufacturers Association (EDMA)—are as follows:  
 
• Market size of roughly €100 billion (around 28% of the global market). 
• Average growth 4% per annum.  
• Positive trade balance of €15.2 billion in 2013 (excluding in vitro diagnostics), 
more than a twofold increase since 2006. (In comparison, the United States 
trade surplus is €5 billion.) 
• United States was the major export destination (41% of exports) as well as 
supplier to the European medical technology market (65% of imports) 
• Almost 25,000 companies, of which around 95% are SMEs with less than 250 
employees.  
• Industry employs 575,000+ overall. 
• Around 500,000 medical technologies currently available.  
• Average product life-cycle of 18–24 months. 
• 10,668 patent applications were filed with the European Patent Office (EPO) in 
2013 (~7% of all applications). 
• On average EU Member States spend 10.4% of their GDP on healthcare and 
medical technology accounts for only 7.5% of total healthcare expenditure. The 
7.5% may be further divided into 6.7% expenditure on medical devices and 
0.8% on in vitro diagnostics. 
 
Regarding the above data, it should be noted that medical technology, as used by 
MedTech Europe (2014: 6), refers to “medical devices, in vitro diagnostics, imaging 
equipment and e-health solutions used to diagnose, monitor, assess predispositions 
and treat patients suffering from a wide range of conditions”—unless otherwise 
specified—and, thus, medical devices make up only a portion of the cited figures.  
 
The medical device industry faces a number of challenges, but the following have 
stood out in several industry reports and news articles. First, due to governments 
aiming to curb healthcare expenditures, companies must be able to demonstrate 
enough benefits to justify the costs (Eucomed, 2014). This is not a simple task and 
failure to do so would likely inhibit market access. Second, the EU is currently revising 
the medical device directives and proposing for a Regulation on medical devices to 
replace directives 90/385/EEC and 93/42/EEC (EC, 2014b). The new Regulation was 
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intended to be adopted in 2014 and come into effect in 2015–2019 (EC, 2012), but at 
the end of 2014 several outstanding issues requiring further discussions persisted and 
the matter remained uncompleted (European Parliament, 2014 & 2015). Nevertheless, 
when concluded new expenses impacting especially European SMEs would be 
created. (Eucomed, 2013) Third, medical device security and cybersecurity concerns 
have been raised over the last years. The issue has received notable media coverage 
after the U.S. Food and Drug Administration (FDA) issued a warning regarding 
cybersecurity for medical devices and hospital networks on 13 June 2013, and 
numerous reports by information security experts on the ease of hacking medical 
devices have emerged (FDA, 2013; Halperin, et al., 2008; Robertson, 2012; Basu, 
2013; Zetter, 2014). 
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3 Demography of England  
 
3.1 Population structure and life expectancy 
 
According to the Annual Mid-year Population Estimates, 2013, published by the Office 
for National statistics (ONS) (2014a), the population in the UK as a whole grew to 64.1 
million—growth of 0.63% from the previous year and well above the EU average of 
+0.21%—and in England to 53.9 million—growth of 0.70%. Immigration was 
responsible for 46% of the increase and natural change (i.e. births minus deaths) for 
53% (ONS, 2014a). With this dataset one may state England’s population to have 
formed approximately 84% of the UK population in 2013. The report further states 
England to have had the greatest 10-year average population change of the four UK 
countries in percentage terms with +0.79%. According to ONS, the UK population is 
projected to reach 68.5 million in 2023, 72.5 million in 2033, and 82.4 million in 2063 
(2014b).  
 
The population structure for the UK is displayed as a population (or age) pyramid in 
Figure 1. One should note that the pyramid displays UK data, not England alone, and is 
flat on top since “the pyramid stops at age 89” (ONS, 2014a: 10-11). Population 
pyramids are used to “track and compare changes in population age distribution over 
time” and looking at Figure 1 we see a block-resembling shape typical of an 
industrialised society with low death-rates, and indicative of effective public health 
measures and good socioeconomic conditions (Merrill, 2010). As one may observe, the 
number of people aged 65 and over has increased over the decade, more so in men 
than women, and the number of births has increased lately. Despite the pyramid 
neglecting to give a comprehensive view of the most elderly population in the UK, 
other data convey the significance of the “very old”; in 2013 there were more than 0.5 
million people aged 90 and over living in the UK and the number of centenarians went 
up by 71% in the decade leading up to 2013 (ONS, 2014c). The population aged 90 
and over made up just 0.8% of the population in 2013, but the trend appears upwards 
both in absolute terms as well as relative to other population groups (ONS, 2014c), 
which relates to the topic of an ageing population discussed more in the next sub-
section.  
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Figure 1: Population structure in the UK, 2013 (ONS, 2014a: 10) 
 
In general, England has fared well when it comes to improving life expectancy, which 
may be considered to reflect a functioning health service system among other 
properties of a welfare state. Based on data for England 2011–2013, a newborn boy 
could expect to live 79.21 years while a newborn girl 82.96 years—figures, which were 
76.13 and 80.68 for 2001–2003 data, and 73.59 and 78.98 for 1991–1993 data (ONS, 
2014d). However, geographical variations do exist especially between London and the 
Northern regions, with the former having some 2.5 years higher life expectancies for 
both baby boys and girls, despite the latter experiencing more rapid increases in life 
years since the 1990s than the southern areas (excluding London) (ONS, 2014e).  
 
The increasingly long lives also impact the causes of death, the most common of which 
are conditions mainly diagnosed at an older age. According to ONS (2014f), there were 
506,790 all cause deaths—51.5% women and 48.5% men—in England and Wales in 
2013. (Data for England alone is unavailable.) The five most common causes of death 
and their proportion of all deaths in the order of prevalence are as follows.  
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• neoplasms (i.e. cancer) 28.7%  
• diseases of the circulatory system 27.7% 
• diseases of the respiratory system 14.6% 
• mental and behavioural disorders (incl. dementia) 7.5% 
• diseases of the digestive system 4.8% 
 
There have been some changes in the statistics from a decade ago. In 2003 in the 
same population set there were a total of 538,254 deaths with diseases of the 
circulatory system as the most common cause (38.2%), neoplasms second (25.9%), 
diseases of the respiratory system third (14.0%), diseases of the digestive system 
fourth (4.6%) and external causes of morbidity and mortality fifth (3.1%) (ONS, 2004). 
As one may observe cancer deaths have increased slightly in both absolute and relative 
terms, while deaths from diseases of the circulatory system have decreased. Deaths 
assigned to mental and behavioural disorders are up by over 150% and 97.6% of them 
in 2013 were due to various forms of dementia (ONS, 2014f). 
 
3.2 Notable trends and their impact on demand for health services 
 
When discussing demographics it is important to observe significant factors and 
prevalent trends in order to understand how the population is changing. This is 
meaningful to the main topic of the thesis since the aforementioned has a significant 
impact on the health of the nation and, thus, demand of various types of health 
services. 
 
First, the population is ageing and the King’s Fund (2015a) projects the number of 65–
84 year-olds to increase by 39% to 10.9 million and the number of over 85 year-olds 
106% to 2.6 million in 2012–2032. They further state that, despite population growth 
in lower age groups as well, this would bring the old age dependency ratio—i.e. ratio 
of those under the working age or over the state pension age to those aged 15–64 
who are in the labour force—up from 31.4% to 34.9% during the same time period 
even if higher state pension ages were implemented (although they did not elaborate 
on the possible new pension age).  
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This trend will inevitably increase healthcare costs, considering most people over 65 
have a chronic condition, most of those over 75 have two or more, and co- and 
multimorbidity tends to increase with age (Oliver et al., 2014:10). This is further  
illustrated in figure 2, which displays data derived from Scottish medical practices and 
local patients making up approximately a third of the Scottish population (Barnett et 
al., 2012). (It should be noted that individuals living in highest levels of socioeconomic 
deprivation saw onset of multimorbidity 10–15 years earlier than the most affluent 
ones.) With older people experiencing a higher incidence rate of certain severe 
conditions such as dementia which independently are associated with longer hospital 
stays, as well as having complex co- and multimorbidities, it is not surprising the mean 
length of stay for all hospital admissions increases with age-group and the over 65 
year-olds account for nearly 80% of the emergency admissions staying in the hospital 
for longer than two weeks (HSCIC, 2013a: 38; Poteliakhoff and Thompson, 2011: 3). 
 
 
Figure 2: Prevalence of multimorbidity in Scottish patients by age group (Adapted from 
Barnett et al., 2012) 
 
In addition to ageing, a prominent demographical trend worth mentioning is the 
increasing proportion of overweight and obese people. According to a report by the 
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Health and Social Care Information Centre (HSCIC, 2013b), 65% of men, 58% of 
women, and around a third of children aged 2 to 15 in England in 2011 could be 
classified as either overweight or obese. These figures are alarming since statistically 
medical costs increase as a person’s body mass index (BMI) increases (figure 3). 
Spending on direct medical costs of conditions related to being overweight or obese 
are around £6 billion (equal to some 5% of NHS’s budget), not to mention the £10 
billion spent on diabetes (Dobbs et al., 2014: 22) and other costly conditions 
associated with excess weight. According to some projections the number of obese 
people in the UK will increase by a further 11 million by 2030 (Wang et al., 2011). As 
well as bringing up costs, this worrying development will exert substantial pressure on 
health services. 
 
 
Note: “Includes primary care, general practitioner prescriptions, hospitalization, 
accident and emergency, and outpatient care. 2003 values taken from Tigbe et 
al. (2013) adjusted using 2012/13 Fédération Internationale de Médecine du 
Sport and Health Examination Survey data on per capita UK costs in each 
category” 
Figure 3: UK medical costs by BMI group, 2012 (Adapted from Dobbs et al., 2014: 21) 
 
 
Finally, other factors commonly considered to putting the English population’s health at 
risk include alcohol consumption and binge drinking, tobacco use, high blood pressure 
805 
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and cholesterol levels, and insufficient activity levels. Boyle (2011: 11) reports alcohol 
consumption to have increased among both men and women between 1998 and 
2003—perhaps most worryingly as binge drinking among young women—raising the 
number of alcohol related deaths. Chief Medical Officer for England Dame Davies 
(2012: 196) states smoking to be “the single greatest cause of preventable illness and 
early death in England, and a major contributor to health inequalities” with 79,000 
deaths a year being attributable to smoking along with a price tag of £5.2 billion in 
2005/06 for the NHS. Despite the worrying statistics she states smoking to have 
decreased significantly over the last three decades. Tying together with obesity and 
poor dietary choices, high blood pressure and cholesterol are mentioned by Davies 
(2012: 205–207) as further risk factors. These have been linked with chronic 
conditions such as cardiovascular disease, which, as established earlier, is a major 
cause of death in England. Lastly, she raises concerns over low levels of physical 
activity. Due to exercise and an active lifestyle reducing risk of several medical 
conditions—physical and mental—the figures stating that in 2008 an average of 39.2% 
of men and 28.7% of women met the recommended level (i.e. 150 minutes of 
moderate intensity activity over a week) may be considered less than ideal.  
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4 England, the British Government, and responsibility for health 
services  
 
England is a part of the United Kingdom (UK)—a Western European Commonwealth 
realm consisting of four countries: England, Northern Ireland, Scotland, and Wales. 
The UK is a constitutional monarchy with Queen Elizabeth II as the head of state and 
Prime Minister David Cameron, Leader of the Conservative Party, as the head of 
government (CIA, 2014). Developing and implementing policy and drafting laws are 
done by the government—also known as the Executive—which, in essence, runs the 
country, whereas the parliament—also known as the Legislature—scrutinises the work 
of the government, debates and passes all laws, and sets taxation. The prior is formed 
by the Prime Minister and a number of Ministers chosen by him from the House of 
Commons and the House of Lords, which then together form the latter (UK 
Government, 2014; UK Parliament, 2014a). The current Conservative/Liberal coalition 
government was formed on 10 May 2010 (UK Government, 2014), but a general 
election is to be held on 7 May 2015, which may bring about change (UK Parliament, 
2015).  
 
Since devolution in 1999, responsibility for certain policy areas, such as health, has lain 
with the devolved administrations (UK Parliament, 2014b; UK Government, 2014). Due 
to this the public health services are provided by separate systems in each country and 
the ultimate responsibility for healthcare lies with the UK Government in England, the 
Northern Ireland Assembly in Northern Ireland, the Scottish Government in Scotland, 
and the Welsh Assembly Government in Wales (NAO, 2012; NHS, 2015a). 
Respectively, the public health services are called the National Health Service (NHS), 
Health and Social Care in Northern Ireland (HSC), NHS Scotland, and NHS Wales, but 
because the present thesis focuses on England alone, “NHS” will only refer to the NHS 
in England from this point on, unless further specified. While the Department of Health 
(DH) is responsible for strategic leadership and funding for health and social care in 
England, the Secretary of State for Health—Jeremy Hunt MP since September 2012—
has overall responsibility for the work of the DH (NHS, 2015b).  
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5 Public health services in England 
 
5.1 Overview of the system 
 
In England public healthcare is delivered by the National Health Service (NHS)—an 
independent body separate from the government—which was established on 5 July 
1948, to provide health services for all UK citizens free at the point of delivery. The 
NHS provides a wide coverage of primary, secondary and specialist services, including  
 
• general practitioner (GP) services 
• hospital services 
• emergency and urgent care (i.e. A&E) 
• mental health services 
• dental services 
• eye care services 
• pharmacy services 
• social care 
(NHS, 2015c) 
 
A GP is typically the first point of contact for a patient and individuals must register 
with a GP practice primarily in their catchment area. If deemed necessary, the GP will 
then refer the patient to a hospital or specialist (NHS, 2015d).   
 
Services are commissioned by Clinical Commissioning Groups (CCGs) and NHS 
England—a public body not to be confused with the NHS—who may acquire services 
from any service provider that meets the criteria. Commissioning services is examined 
more closely in section 5.3.1. 
 
In general the founding principal of the NHS, “free at the point of delivery”, is 
applicable, but some services such as ophthalmic and dental services, and outpatient 
medications require payment (Boyle, 2011: 96). Depending on a patient’s financial 
situation, however, those in low-income brackets may be able to fully or partially 
reclaim the money spent or receive service vouchers (NHS, 2015e).  
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In addition to the public healthcare, private sector health services are widely available 
in England as well. A patient may acquire care directly from a private provider or 
receive NHS-funded care provided by one (King’s Fund, 2014). Private health services 
are mainly paid for by voluntary health insurance, as “out-of-pocket” payments by 
individuals, or by the NHS for its patients. This topic will be further discussed in section 
5.3.3. 
 
Finally, it should be mentioned that due to the new Health and Social Care Act 2012 a 
massive reorganisation of the public health system took place on 1 April 2013, when 
the legislative changes came into effect (NHS England, 2014: 7). The event saw some 
components of the old system abolished, new ones created, and responsibilities of 
certain bodies altered. This thesis focuses on the post-reform settings, although in 
some cases the old system is mentioned and data from time before the transformation 
used.  
 
5.2 Healthcare expenditure 
 
Statistics on healthcare expenditure are published for the UK as a whole. According to 
ONS (2014g), total spending on healthcare in the UK grew at an average annual rate 
of 8.1% in 1998–2009 before slowing down to 1.6% in 2010–2012. In monetary terms 
this translates to an increase from £54.6 billion in 1997 up to £144.5 billion in 2012. 
Considering population growth and other factors, some increase would be anticipated, 
but—within the same timeframe—per capita spending more than doubled as well, from 
£936.61 to £2268.12 (Postins and Payne, 2014: 4). 
 
As a proportion of GDP (%), healthcare spending in the UK used to be relatively low 
when compared internationally, but reached the EU average in 2006 and is currently 
slightly above it (table 1) (OECD, 2014a: 122). This increase was influenced primarily 
by Labour government policy to increase public spending on healthcare in the early 
2000s (Boyle, 2011: 72). Additionally, in the late 2000s the financial crisis slowed down 
GDP growth, even turning it negative in 2009, which raised the proportion of 
healthcare spending, although naturally this affected other nations in the EU as well 
and has somewhat reversed as the economy has recovered (Postins and Payne, 2014: 
5).  
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Table 1: Total health expenditure as a share of GDP in 2000–2012, selected European countries 
(OECD, 2014b & 2015) 
 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
UK 6.9 7.2 7.5 7.8 7.9 8.1 8.3 8.4 8.8 9.7 9.4 9.2 9.3 
EU28  7.3 7.5 7.7 8.0 8.0 8.2 8.1 8.1 8.4 9.0 8.8 8.7 8.7 
France 10.1 10.2 10.6 10.8 10.9 10.9 10.9 10.8 10.9 11.6 11.6 11.5 11.6 
Germany 10.4 10.5 10.7 10.9 10.7 10.8 10.6 10.5 10.7 11.8 11.6 11.2 11.3 
Italy 7.9 8.1 8.2 8.2 8.5 8.7 8.8 8.5 8.9 9.4 9.4 9.2 9.2 
Spain 7.2 7.2 7.3 8.2 8.2 8.3 8.4 8.5 8.9 9.6 9.6 9.4 9.3 
(Note: France, Germany, Italy and Spain have been chosen for the comparison by the author, 
because they are the four EU countries closest to the UK in terms of population size.) 
 
In the UK public expenditure makes up 84.0% and private 16.0 % of the total health 
expenditure (Postins and Payne, 2014: 11). Some fluctuation has occurred over the 
years—influenced, for example, by the aforementioned policy decisions—but public 
sector has always been responsible for the majority of healthcare spending. Looking at 
other countries, the share of public financing is higher in just three European 
countries—the Netherlands, Denmark and Norway—as is the share of health 
expenditure from the total government expenditure, which in the UK stood at 16.2% in 
2012 (OECD, 2014a: 129).  
 
Overall, the UK has a similar or lower total health expenditure than its European peers. 
The share of public expenditure is high, as is the share of health spending from all 
government spending. Although this is the current situation, government policy and 
the economic climate, among other things, have considerable impact on the matter, 
which may result in significant changes. This should be kept in mind when considering 
the near future, especially with a general election approaching in May 2015, as well as 
some friction in the UK-EU relations with even a referendum on the UK’s EU 
membership conversed (Oliver, 2013).  
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5.3 The National Health Service (NHS)  
 
5.3.1 Basic structure and commissioning of services  
 
Many public health services in England, such as hospitals, are managed by trusts and 
foundation trusts—not to be confused with the similar legal term—which are 
organisational units that provide health and care services of a certain function. 
Foundation trusts differ from trusts in that they are independent legal entities with 
unique governance arrangements where local people can become members or 
governors, and a board of governors is involved in strategic planning (NHS, 2015f). 
They are self-standing and self-governing organisations, which may raise capital from 
the public or private sector and retain financial surpluses. Trusts on the other hand are 
directed by the government in strategic decisions and are financially accountable to the 
government (NHS England, 2014: 15). Foundation trusts are overseen by Monitor, 
whereas trusts are overseen by the NHS Trust Development Authority (NHS TDA) that 
additionally assists a trust in its transition to foundation trust status.  
 
Local services from the trusts and foundation trusts are commissioned by clinical 
commissioning groups (CCGs), which consist of clinicians like GPs and nurses. The 
CCGs are a novel component of the system and were established in 2013 when the 
NHS underwent a large-scale reorganisation as a result of the new Health and Social 
Care Act 2012. Prior to this the task of planning and commissioning services was 
mainly done by primary care trusts (PCTs), which no longer exist, but are mentioned in 
older materials. A key objective in giving these duties to CCGs was that the clinicians 
that form them were considered closer to the patients in their area and, thus, more 
attuned to their healthcare needs (King’s Fund, 2013). Locally commissioned services 
include most secondary care services (e.g. planned hospital care, urgent and 
emergency care, community health services, and mental health services) and may be 
commissioned from any service provider (e.g. NHS hospital, private sector provider, 
social enterprise, or charity) as long as they meet NHS standards and costs, the 
guidelines provided by the National Institute of Health and Care Excellence (NICE), and 
data on service providers by the Care Quality Commission (CQC) (NHS, 2015b). In 
2013, responsibility for planning and delivering primary care and specialist services was 
taken on from the PCTs by NHS England, originally known as the NHS Commissioning 
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Board—an executive non-departmental public body of the DH—that additionally 
oversees and allocates financial resources to the CCGs (NHS, 2015f; NHS England, 
2015a). 
 
The latest figures provided by the NHS Confederation (2014) regarding the number of 
providers and commissioners of NHS services in England are as follows:  
 
• 211 clinical commissioning groups […] 
• 156 acute trusts (including 101 foundation trusts) 
• 56 mental health trusts (including 41 foundation trusts)  
• 34 community providers (16 NHS trusts, 2 foundation trusts and 16 social 
enterprises) 
• 10 ambulance trusts (including 5 foundation trusts) 
• c. 8,000 GP practices 
• 853 for-profit and not-for-profit independent sector organisations, providing 
care to NHS patients from 7,331 locations 
 
5.3.2 Funding and spending 
 
Health services in England are financed through general taxation, national insurance 
contributions (NICs), and some patient payments, which in 2011 accounted for 80.9%, 
17.9%, and 1.2% of the NHS funding, respectively (Hawe and Cockcroft, 2013: 51). 
Despite some slight fluctuations, general taxation has always been the greatest source 
of finance for the NHS. 
 
The flow of funding in public health services is displayed in figure 4. Money is allocated 
by HM Treasury to the DH that retains a proportion for expenses and funding of other 
bodies, and then allocates the majority of what was received to NHS England. NHS 
England, in turn, retains money for funding nationally commissioned services and 
allocates about 60% of the initial total to CCGs—and in a much lesser extent to local 
authorities—that commission some local health services (NHS England, 2014: 11).  
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Figure 4: Flow of funding in public health services (adapted from NHS England, 2014: 11) 
 
In 2013/14, NHS England received £95.6 billion—80.0% of the total £119.5 billion 
spent by the DH—and it was allocated as follows: 
 
• £65.5 billion to CCGs (incl. £0.9 billion for local authorities) for commissioning 
local services 
• £25.4 billion to NHS England for commissioning national services  
• £1.8 billion for NHS England’s public health responsibilities on behalf of Public 
Health England (incl. immunisation and screening) 
• £1.2 billion surplus carry forward, to be allocated to CCGs and NHS England for 
future investment  
• £1 billion for central health programmes to be administered by NHS England 
• £0.7 billion for technical accounting adjustments 
(NAO, 2014a: 9; NHS England, 2015b) 
 
Significantly, staff costs made up £48 billion and purchase from non-NHS bodies £10 
billion of the total (£119.5 billion) (NAO, 2014a: 11). 
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The DH ran surpluses in 2011/12 and 2012/13, but spending requirements are 
projected to go up and according to NAO (2014a: 18), “NHS England recently 
estimated that continuing with the current model of care will result in a total gap 
between spending requirements and resources available of around £30 billion by 
[2020/21]”. Furthermore, £20 billion in efficiency savings are expected to be delivered 
by the NHS between 2011/12 and 2014/15 through the Quality, Innovation, Prevention 
and Productivity (QIPP) programme (HM Treasury, 2013: 35). Fortunately, the 
Parliament has confirmed that, despite austerity measures, health funding will be 
protected until 2015/16—unlike funding for many other departments facing cuts—but 
this means an increase of just 0.1% (in real terms) at a time when public health 
services are under mounting pressures (discussed in section 5.3.4) and certain 
demographic trends—such as the ageing population mentioned earlier—will contribute 
to increasing demand in the future as well (NAO, 2014a: 13, HM Treasury, 2013: 30). 
 
Furthermore, grave concern has recently been expressed over the financial state and 
outcomes of trusts and foundation trusts. As detailed by Murray et al. (2014: 3), the 
system appeared to operate rather well until 2013/14, and meet demand efficiently 
while simultaneously maintaining quality of care, but in 2013/14 several overspends 
occurred; the NHS Trust Development Authority (TDA) reported a net deficit of £241 
million for the NHS trusts—instead of the planned £76 million—and just over 25% of 
the trusts (25 trusts) ended the financial year in deficit, compared to a mere 5% in 
2012/13. In the same time period the foundation trusts, which unlike trusts are “not 
required to break even every year”, were experiencing something similar; 27.9% of 
them (41 foundation trusts) reported deficits taking their gross deficit to £309 million 
for 2013/14 compared to 21 foundation trusts running a deficit and a gross deficit of 
£160 million in 2012/13 (Monitor, 2014a). The situation has not shown signs of 
improvement, rather quite the opposite, and a recent Quarterly Monitoring Report 
conveyed the pessimism and worry of NHS trust finance directors with 36.7% (n=90) 
forecasting that their trusts will end 2014/15 in deficit (Appleby et al., 2014).  
 
All in all, growth of government spending on public health services has slowed down in 
the last years. The NHS is facing challenges in managing efficiently at a time of 
austerity, and coping with various requirements and pressures. Sustainable ways of 
20 
 
 
achieving long-term savings, while maintaining quality of care, are needed in order for 
the NHS to fulfil its mandate and secure the delivery of public health services.  
 
5.3.3 Health service commissioning from the private sector  
 
Public health spending on non-NHS bodies was £10 billion in 2013/14, and, as 
established, commissioners of public health services may purchase services from 
private sector companies, as long as the provider meets set criteria. The “formal 
expansion of non-NHS provision” started in 2003 with independent sector treatment 
centres (ISTCs)—private sector units providing services only to NHS patients—and 
continued in 2008 with the Any Qualified Provider (AQP) policy—extending patient 
choice for elective care to all compliant providers (Arora et al., 2013: 14) This was 
aimed at reducing waiting times (by increasing capacity), improving patient choice, 
introducing competition in order to encourage NHS providers to develop their services, 
and allowing the NHS to utilise private sector capacity more cost-effectively (Naylor 
and Gregory, 2009: 2).  
 
In 2012, NHS purchase accounted for 27.5% (or £1.2 billion) of private hospital 
revenue in the UK, up from just under 10% in 2004 and projected to reach nearly 29% 
in 2013 (LaingBuisson, 2013; King’s Fund, 2014: 2). The remainder (in 2011) came 
from private medical insurance (PMI), individuals paying “out-of-pocket”, and overseas 
patients—generating approximately 56%, 15%, and 2.8%, respectively—with some 
fluctuation in the ratios over the years. While private expenditure on all healthcare (in 
the UK) decreased on average 2.1% per annum in 2007–2011 and treatments paid by 
individuals out-of-pocket declined, spending by the NHS on non-NHS providers in 
England increased by 55% from £5.60 billion in 2006/07 to £8.67 billion in 2011/12 
(Arora et al., 2013: 8, 12). Thus, despite recent decline in overall private health 
expenditure influenced by the financial crisis and, potentially, increase in public 
spending and volume of NHS activity in the 2000s, private sector providers have 
strengthened their position as suppliers of NHS-funded healthcare.  
 
In the near future, as projected by Blackburn (LaingBuisson, 2013), the severe 
financial pressures of the NHS are expected to result in flat demand for health services 
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from non-NHS providers. Nevertheless, private provision of publicly funded health 
services has become a solid feature of the healthcare system in England.  
 
5.3.4 Contemporary issues and challenges 
 
As one might expect, a large organisation such as the NHS is not without its problems 
and challenges. The financial difficulties were already discussed in part 5.3.2, but three 
more topics are examined in this final sub-section on the NHS: Demand and increased 
volumes; staff and staffing; and quality of care. These were selected, because they 
have been prominently mentioned in industry reports and media publications.  
 
5.3.4.1 Demand and increased volumes 
 
Demand for public health services has increased significantly over the years and 
figures provided by NHS England (2013: 15–16) convey the magnitude of the upward 
trends:  
 
• The average number of consultations in general practice per patient rose from 
4.1 to 5.5 per year between 1999 and 2008 indicating greater demand and 
complexity in primary care. 
 
• There were 6.8 million attendances at walk-in centres and minor injury units in 
2012/13, and activity at these facilities has increased by around 12 per cent 
annually since data was first recorded a decade ago. 
 
• Attendances at hospital A&E departments (officially referred to as Type 1 and 
Type 2 A&E) have increased by more than two million over the last decade to 
16 million. 
 
• The number of calls received by the ambulance service over the last decade 
has risen from 4.9 million to over 9 million. 
 
• Emergency admissions to hospitals in England have increased year on year, 
rising 31 per cent between 2002/03 to 2012/13. 
 
Health service providers are under severe pressure from acute cases whilst the waiting 
lists are expanding. This results in breaching targets. Recently the NHS has failed to 
meet target waiting times frequently in A&E, elective treatment, and cancer screening 
services, in addition to ambulance services missing target response times for the most 
urgent calls (Dorsett and Shi, 2014: 1-2; Campbell, 2014; Nuffield Trust, 2014a: 10–
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11). The total waiting list for elective treatment stood at 3.13 million patients in 
October 2014, although the actual figure might be as high as 3.30 million if non-
reporting trusts submitted their figures (Appleby et al., 2014). One should note that in 
2014 the National Audit Office (NAO) (2014b: 20–28) identified inconsistencies (i.e. 
local variations and errors) in some trusts’ methods of recording waiting times for 
elective care—resulting in under- and over-recording—which is why these figures 
should be viewed with caution and may not be directly comparable. Nevertheless, the 
NAO found waiting times to have been under-recorded in 129 cases and over-recorded 
in 22, with the net effect of errors being an under-recording of 21 days (mean), which 
may suggest a more severe problem than published statistics let on and, thus, the lack 
of fully reliable data on the subject should not be basis for disregarding the presence 
of an issue.   
 
Overall, NHS England (2013: 16) state that considering the significant increases in 
demand and the trend setting to continue as people live longer with increasingly 
complex comorbidities, their current services are unsustainable.  
 
5.3.4.2 Staff and staffing 
 
Due to government policy the number of clinical staff has gone up since 2000 (Boyle, 
2011: 194). The NHS hospital and community healthcare staff (medical and dental) per 
10,000 population increased from 13.00 in 2001 to 18.70 in 2011 (Nuffield Trust, 
2015), and the NHS employed 23,531 nurses more in 2013 than it did a decade prior 
(NHS Confederation, 2014). This has brought statistically low numbers of doctors and 
nurses (relative to population) higher and closer to OECD and EU averages, although 
the number of practicing physicians still remains rather low at 2.8 per 100,000 
population compared to the EU28 average of 3.4 (OECD, 2013: 65, 77; 2014a: 63, 67). 
Additionally a UK nursing labour market review, commissioned by the Royal College of 
Nursing (RCN) (RCN, 2014: 10), points out that growth in the number of NHS England 
qualified nursing and midwifery staff (full-time equivalent) ceased in 2009/10 and the 
figures have been in decline ever since. They also call attention to ageing of the 
nursing workforce; in 2012, 44.8% of the NHS qualified nursing staff in England was 
aged 45 or over and once individuals in this sizeable group reach retirement age, 
significant replacement requirements will ensue.  
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Moreover, the use and reliance on agency staff has increased lately and raised 
concerns over the costs of this tactic at a time when efficiency gains and savings are 
desired. As Dorsett and Shi  (2014: 1, 21) argue in their quarterly report on NHS 
foundation trust sector performance,  
 
An increase in the number of patients being treated combined with high use of 
contract and agency staff and a need to make cost savings, has put NHS 
foundation trusts (NHSFTs) under unprecedented financial and operational 
pressure. 
 
They further state that although the foundation trusts have aspired to curb expenditure 
on contract and agency staff, they actually spend double the planned in Q1 of 2014/15 
(i.e. £391m vs. £189m), and that, overall, agency staff costs as a percentage of total 
staff costs has increased by around 20% annually in the last two years. Table 2 below 
displays annual spending by NHS on agency and contract staff (including locums) since 
May 2010. Besides cost, over-reliance of unregistered and temporary staff may present 
a quality-of-care issue, because there are often limitations on the clinical tasks 
temporary staff may perform (Keogh, 2013: 22). 
 
Table 2: Spending on agency and contract staff (incl. locums) in the NHS since May 2010 
(Poulter, 2014) 
 
Year Foundation trusts Trusts 
  (£ million) (£ million) 
2010/11 854.7 n/a* 
2011/12 907 n/a* 
2012/13 1,101.0 n/a* 
2013/14 1,396.2 1,209.1 
Total 4,258.9 1,209.1 
*Before 2013/14 the expenditure of agency and contract staff was not provided separate from 
"non permanent NHS staff".  
 
Finally, concerns over work morale and welfare of the workforce have been raised. The 
percentage of NHS staff reporting they have been ill due to work-related stress has 
increased significantly since 2008/09, averaging 38% in 2013, across all NHS 
organisations with higher figures in individual trusts (Nuffield Trust, 2014a: 17). In 
addition, a recent Quarterly Monitoring Report—based on an online survey of 90 NHS 
trust finance directors and 43 CCG finance leads—showed that staff morale was the 
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most often selected option to the question, “Which aspects of your organisation's 
performance are giving you most cause for concern at the moment? Please select top 
three” (Appleby et al., 2014). This is troubling, because research suggests a strong 
relationship and even a causal link between the wellbeing of healthcare staff and 
performance outcomes (Boorman, 2010; Maben et al., 2012).  
 
5.3.4.3 Quality of care  
 
When compared with EU averages or Western European countries with the most 
similar size populations, the UK falls behind in several quality of care indicators, such 
as infant mortality, avoidable hospital admissions from asthma and chronic obstructive 
pulmonary disease (COPD), as well as survival rates for certain cancers, heart attacks 
and ischemic strokes (appendix 1) (OECD, 2014a; De Angelis et al., 2014). Looking 
more closely at the avoidable admissions, Blunt (2014: 12-13, 17-18) described that in 
4/2001–3/2013 potentially avoidable emergency admissions for ambulatory care 
sensitive (ACS) conditions—i.e. a specific subset of 27 conditions where emergency 
admissions may be avoided by preventive management in the community—accounted 
for 20% of all emergency admissions and went up 48% versus 34% for non-ACS 
conditions. Highest incidence rates occurred in the elderly, children under 5 years of 
age, and the most socioeconomically deprived groups.  
 
In addition, England has seen scandalous revelations regarding quality of care in 
individual healthcare establishments. During the last decade, a number of public 
inquiries have been launched to conduct reviews into the quality of care of several NHS 
hospitals with abnormally high mortality rates, perhaps the most prominent of which 
was the Francis inquiry into failings at the Stafford hospital run by Mid Staffordshire 
NHS foundation trust (Francis, 2013). The final report published in 2013 highlighted 
numerous issues—stemming from, for example, cost-cutting, understaffing and 
focusing on things other than quality of care—as well as offered 290 recommendations 
aimed at changing culture and practice in several health service related organisations 
(BBC, 2013; Nuffield Trust, 2014b: 7). Official responses have been issued by the 
Government, along with a number of the organisations mentioned in the report, and 
most of the recommendations made by Francis were accepted by the DH in full (DH, 
2014; Nuffield Trust, 2014b: 4).  
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Nevertheless, one should acknowledge that—despite the UK being unable to catch up 
to its European counterparts—improvements in the quality of care indicators 
mentioned earlier have been made over the years. Moreover, out of the four UK 
countries, England does best on some significant indicators such as life expectancy and 
rate of amenable mortality—i.e. premature deaths (under age 75) avoidable through 
better care and “a good indicator of quality of care at the system level”—while having 
less nurses per 1,000 population and lower healthcare spending per person than the 
other UK countries (Bevan et al., 2014).  
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6 Monitoring and regulation  
 
Healthcare services and medical devices available in England are monitored and 
regulated by several bodies in the EU and England/UK. For the purpose of this thesis 
only those concentrated on areas relevant to Medieta as a medical device 
manufacturer, along with the principal national bodies responsible for monitoring NHS 
activities are included. The first section briefly introduces the EU regulation and is kept 
short seeing as Medieta has already acquired both a CE marking and ISO certification, 
while the second looks at national bodies responsible for monitoring and regulating the 
NHS.  
 
6.1 EU regulation and quality assurance relating to medical devices 
 
As a member of the European Union (EU), the UK must abide by EU regulations and 
directives including the Council Directive 93/42/EEC concerning medical devices and 
Council Directive 90/385/EEC relating to active implantable medical devices. While EU 
regulations apply directly and do not need to be transposed into national law, all EU 
administered directives and amendments are currently implemented by four sets of UK 
regulations as stated below (MHRA, 2013a; MHRA, 2014a).  
 
• Statutory Instruments 2002 No. 618 (Consolidated legislation) 
• The Medical Devices (Amendment) Regulations 2003 No. 1697 (Amendments to 
cover the re-classification of breast implants and additional requirements covering 
devices utilising materials from TSE susceptible animal species) 
• Medical Devices (Amendment) Regulations 2007 No. 400 (Amendment to cover the 
re-classification of total hip, knee and shoulder joints) 
• Medical Devices (Amendment) Regulations 2008 No. 2936 which transpose 
Directive 2007/47/EC into UK law 
 
Nevertheless, change is under way and EU has planned on replacing the 
aforementioned council directives with new regulation on medical devices, as 
mentioned in section 2.3. When in effect, this would impose new requirements on 
device manufacturers. 
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Currently, in order for a medical device manufacturer to place their product on the 
market in the European Economic Area (EEA), the device must bear a CE marking to 
indicate it complies with set standards (Council Directive 93/42/EEC). A CE marking 
may be obtained from a Notified Body in any EU country, appointed by a Member State 
to carry out conformity assessment (EC, 2014a).  
 
In addition, numerous voluntary medical device standards exist. These have been 
published by the International Organization for Standardization (ISO), as well as the 
European standardisation organisations the European Committee for Standardization 
(CEN) and the European Committee for Electrotechnical Standardization (CENELEC) 
(ISO, 2014a; EC, 2013).  
 
6.2 National monitoring and regulation of medical devices and public health services 
 
The Medicines and Healthcare Products Regulatory Agency (MHRA) is “responsible for 
regulating all medicines and medical devices in the UK by ensuring they work and are 
acceptably safe”. (MHRA, 2014b) In essence, the MHRA is gatekeeper to market when 
it comes to medicines, medical devices and healthcare equipment, in addition to which 
it investigates harmful incidents regarding the aforementioned (MHRA, 2014c). The 
MHRA also oversees and audits UK’s notified bodies (as the competent authority) and 
must be notified of any clinical trials within the UK, which aim at obtaining CE marking 
(MHRA, 2013b, 2014d). If non-compliance is detected or if adverse incidents or 
security concerns regarding medical devices are reported to the MHRA, an 
investigation will be launched (MHRA, 2014e). 
 
Recommendations on several healthcare topics—e.g. treatment on specific conditions, 
pharmaceuticals, and use of health technologies—are given to the NHS by NICE, a Non 
Departmental Public Body (NDPB) accountable to its sponsor department the DH 
(NICE, 2014). In order to avoid confusion between the activities of NICE and MHRA it 
should be noted that,  
 
MHRA is concerned about the relationships between benefits and risks; NICE is 
concerned, inter alia, about the relationships between benefits and costs. As a 
considerable over-simplification, MHRA says a product can be sold while NICE 
says it can be bought (by the NHS) (MHRA, 2008). 
 
28 
 
 
When it comes to health technologies, NICE assesses their “clinical and cost 
effectiveness” through technology appraisals and gives guidance accordingly (NICE, 
2013a, 2013b: 8). Evidence on various aspects of a technology are required—such as 
clinical evidence and an economic evaluation—in order for quality-adjusted life years 
(QALYs) to be estimated and economic analyses—including cost-utility analysis and 
cost-effectiveness analysis—to be conducted (NICE, 2013c). A technology costing less 
than £20,000 per QALY is considered cost effective, while one costing £20,000-30,000 
per QALY may be considered cost effective under conditions. Beyond that a very strong 
case has to be made in order for the technology to be considered efficient use of NHS 
resources (NICE, 2013c).  
 
The final decisions of NICE fall into four categories:  
 
• Recommended for use in line with marketing authorisation from the European 
Medicines Agency (EMA) or MHRA, or with how it is used in clinical practice in 
the NHS. 
• Optimised, meaning recommended for a smaller subset of patients than 
originally stated by the marketing authorisation. 
• Only in research, meaning recommended for use only in the context of a 
research study (e.g. a clinical trial). 
• Not recommended, due to for example, lack of evidence for clinical 
effectiveness, or increased cost-effectiveness compared with current NHS 
practice. 
(NICE, 2015) 
 
Between 3/2000 and 12/2014 NICE published a total of 328 technology appraisals and 
made 540 resulting decisions, of which 335 (62%) were in the “recommended” and 97 
(18%) in the “optimised” categories (NICE, 2015). While a marketable device is being 
appraised, NHS organisations should make decisions on the use of the device locally, 
but once NICE issues national guidance, local recommendations are replaced by them. 
The technology appraisals are typically enforceable three months from the date of 
publication and the NHS is required to provide funding and resources for the medicines 
and treatments recommended (NICE, 2013b).  
 
29 
 
 
Monitor is an executive non-departmental public body of the DH whose key 
responsibilities include regulating NHS foundation trusts, setting required standards to 
all NHS providers, ensuring essential services are provided in an area where a provider 
has encountered severe difficulties, ensuring efficiency and equality of the payment 
system for NHS services, and optimising procurement and competing services (Monitor, 
2014b: 3–4). They work closely with regulatory partners such as the NHS, NHS TDA, 
CQC, National Quality Board, and Competition and Markets Authority.  
 
The CQC regulates numerous health services in both public and private sectors 
including, but not limited to, areas such as hospital care, mental health, primary and 
community services, dental care, and ambulance services (CQC, 2014a: 10). In order 
to ensure the safety, efficiency and quality of care, they register health services that 
meet standards, carry out inspections, and publish reports and performance ratings 
(CQC, 2014b: 5–8). Where non-compliance is met the CQC may issue a warning notice 
or, in more severe cases, prosecute breaches of fundamental standards without a 
warning (CQC, 2014b: 119-120). In 2013/14 there were a total of 39,567 inspections 
(incl. follow-up and responsive) leading to 1,456 warning notices (CQC, 2014a: 11). 
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7 Methodology 
 
7.1 Research objectives and design 
 
The objective of the present thesis is to provide an overview of the public healthcare 
system in England, as well as to explore the factors present in the market and within 
the public healthcare system that might influence the demand for Medieta’s product or 
complicate market entry. The work may be classified primarily as a descriptive study, 
because its purpose is to “gain an accurate profile of events, persons or situations” 
(Saunders et al., 2012: 171). In addition, elements of an explanatory study and 
feasibility study are present, since the thesis is concerned with explaining the factors 
that affect the public healthcare system in England, along with evaluating the 
possibility of market entry, despite excluding specifics of aspects such as Medieta’s 
future plans, finances and product.  
 
7.2 Data collection and analysis 
 
Data collection focused on qualitative and quantitative data, obtained primarily from 
well-regarded official sources, such as the UK Government, DH, ONS, OECD and NAO; 
two UK-based charity think tanks the King’s Fund and Nuffield Trust; and peer-
reviewed journals. Descriptive data on public bodies—such as the NHS England, MHRA 
and NICE—was primarily retrieved from the organisation’s own website. Despite some 
concerns when it comes to secondary data—i.e. it may be originally collected for 
different purposes, the scope may be unfavourable, and there may be problems with 
accuracy—the advantages when doing research on a national, non-domestic market 
and a complex industry are immense, and data collected by international organisations 
and governments may be considered reliable and of high quality due to expertise and 
rigorous methods (Ghauri and Grønhaug, 2010).  
 
Material was searched primarily through Google, EBSCOhost (that displays e.g. 
Elsevier’s publications), and search functions on the organisational websites outlined in 
the previous paragraph. Boolean phrases were used when possible and searches 
included terms such as:  
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commissioning monitoring 
efficiency National Health Service 
England NHS 
European Union population 
expenditure private 
funding public 
health indicators quality of care 
health technology regulation 
health technology assessment statistics 
healthcare trends 
medical devices United Kingdom 
 
Material was collected, aside from few exceptions, before 31 December 2014. No 
material published later was accepted, although some websites and online documents 
were accessed after that point as well. This was a necessary cut-off as new material is 
constantly generated in volumes. Furthermore, due to oversupply of material and 
constant developments of the public health system—including a massive reorganisation 
of the NHS in 2013—reports published in 2013-2014 were favoured. Few sources pre-
2009 were included, but his was mainly due to a great volume of recent, high-quality 
data, rather than systematic excluding of older sources. Naturally, necessary historical 
data and statistics were used. 
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8 Discussion  
8.1 Demand factors for Medieta’s product in public healthcare in England  
 
The public healthcare system in England is under severe pressure and faces numerous 
challenges now and in the future. The population continues to grow as well as age. 
Life expectancy is up and although this is a positive trend, people living longer and the 
absolute and relative number of the old and very old increasing translates to more 
demand for public services, including those provided by the healthcare sector. The 
older tend to have more comorbidities and complex conditions commanding longer 
hospital stays. In addition, growth of the proportion overweight or obese people, as 
well as poor health habits—smoking, alcohol use and insufficient physical exercise, 
among other things—contribute to costly lifestyle conditions and increased patient 
volumes. While the NHS is already struggling to meet demands, whilst not exhausting 
current resources (incl. staff), maintaining quality of care and managing costs, further 
improvements should be made in order to achieve better health outcomes on par with 
EU peers.  
 
It is easy to see a market for Medieta’s device here. The healthcare system requires 
improved efficiency and cost savings, but cannot afford to compromise on care quality, 
which already is an area of concern. A wearable monitoring device that transmits data 
wirelessly for clinical staff to be viewed wherever, accompanied by intelligent software 
that displays the data and automatically alerts of worrying changes in the patient’s 
condition before their health status deteriorates, would have many applications within 
the public healthcare system in England. Based on what is written in the previous 
sections on the demographic trends impacting the demand of health services and the 
current situation and challenges of the system, some possible areas of care and patient 
groups that might benefit from Medieta’s device (referred to as “the device” in this 
section) are:  
 
• Geriatric patients (in hospitals, care homes and home care): Many older 
patients have complex comorbidities and conditions, which may be very difficult 
to treat and command for longer hospital stays. The device would allow care 
staff to be alerted and react promptly to worrying biosignals, whether the 
individual was at home or at a care unit. Thus, care could be delivered earlier, 
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potentially resulting in a better outcome. Additionally, the GPS tracking feature 
might prove useful when caring for and needing to locate an elderly patient—or 
any patient in general—suffering from memory loss or confusion, such as 
someone with dementia. 
 
• Patients requiring emergency care (i.e. those using A&E and ambulance 
services): Using the device, ambulance and A&E nursing staff could monitor 
and collect data from a patient even before they can be seen by a physician. 
This might assist in determining the patient’s health status and prioritising 
those most in need of urgent medical care, which in turn would help avoid 
unnecessary deterioration of the patient’s condition while they wait.  
 
• Individuals with severe, long-term conditions or comorbidities who require 
continuous management (e.g. patients with cancer, coronary heart disease, 
asthma, diabetes, or a combination of conditions): These patients are already 
receiving care and being monitored, however the device would allow 
continuous monitoring instead of only obtaining data at certain intervals and 
provide more insight into how the measurements change over time. It might 
help identify patients who require closer care in order to avoid worsening of 
their condition, especially to the point where it would require an expensive 
hospital admission and treatment in an intensive care unit. On the other hand, 
the device could allow reduce unnecessary appointments for patients whose 
condition and treatment are in balance.  
 
• Post-operative patients and patients who have been treated for a serious event 
(e.g. heart attack or ischemic stroke): The device could bring extra help in 
deciding whether or not a patient is ready to be discharged and allow patients 
to be discharged earlier as well as called back if the device warns of worrying 
changes in the patients condition.  
 
Overall, the key benefit and aspiration with the use of Medieta’s device is to shift focus 
increasingly toward preventive care and allocating care where and when it is most 
needed. It also allows for convenient monitoring of patients who might benefit from it, 
but are not continuously monitored under the current system. With the patient 
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volumes up and projected to increase further, early medical intervention and attaining 
stability for patients—especially those with long-term conditions—would make a 
contribution to avoiding the more labour intensive—and hence expensive—types of 
care such as inpatient hospital care and intensive care, as well as relieving pressures 
on clinical staff and highly busy departments, such as emergency care. Additionally, 
catching negative health events early on and delivering care before a more severe or 
critical state ensues would help decrease need for future treatment caused by 
unnecessary complications or even permanent disabilities due to delayed care, thus, 
contributing to quality of care.  
 
8.2 Key requirements for market access and encouraging purchase of Medieta’s 
device by the NHS  
 
Naturally, all legal requirements for medical devices must be met in order to gain 
market access. Medieta has already obtained a CE marking and relevant ISO 
certification for the software, which must be done for the wearable monitor as well. 
Still, this does not guarantee adoption of the device by the NHS. In order to do so 
Medieta must conclusively show the quality and benefits of the device, but, even more 
crucially, that the purchase and use of the device may be done at an acceptable cost.  
 
It is possible that the NHS would purchase the device of their own accord, but in this 
case the decisions would be made locally. On the other hand, obtaining a 
recommendation for the use of the device from NICE would necessitate the NHS as a 
whole to make the device available and used if a patient’s doctor considered it to be 
clinically appropriate. Since NICE is concerned with the cost and benefit of the new 
technology, a recommendation would not be awarded if a QALY gained through the 
use of the device came at too high a cost. Therefore, Medieta must have high-quality 
data proving both the positive clinical outcomes for patients and the costs in relation to 
these being low enough.  
 
Looking ahead, the European legal framework is likely to experience updates in the 
near future, which may create additional responsibilities and costs to medical device 
manufacturers. On a national level, the new UK government that will be formed after 
the fast approaching general election may bring changes to healthcare policy and 
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funding, impacting NHS purchase among other things. Thus, a European medical 
device manufacturer aspiring to enter the public health services market in England 
must acknowledge and prepare for the possibility that new requirements and priorities 
emerge.  
 
8.3 Limitations of the study and suggestions for future research 
 
Composing a study on the public healthcare sector is challenging in several ways. First, 
everything is live and the situation keeps updating constantly, with new data being 
generated on a daily basis. For this reason it was necessary to select a “cut off date”, 
i.e. 31.12.2014, meaning data published after this would not be accepted. 
Unfortunately it takes time for statistics to be made available so, despite using latest 
figures, most of them are some two or three years old. Furthermore, the large-scale 
reorganisation of the NHS in 2013 may have created special circumstances, which 
generate initial, short-term fluctuations in statistics, or conversely result in meaningful, 
permanent changes, which cannot be identified at such an early stage.  
 
Second, data quality and comparability present an issue when working with secondary 
data. What complicates the matter further is England being a part of the UK. Some 
statistics are available for England alone, while some are obtainable only for the entire 
UK. Similarly, some data is presented for a calendar year—e.g. statistics from OECD 
and ONS—while some data is displayed for the UK financial year running from 1 April 
to 31 March—e.g. NAO and financial data in general. Whether the data regards 
England or the UK, and calendar or financial year is noted throughout the thesis, but 
this results in poorer comparability.  
 
Finally, due to the vastness and complexity of the subject some data and subtopics had 
to be excluded. This was in order to provide a comprehensive overview of the system 
without being too superficial and still giving attention to areas of special interest to the 
thesis’ commissioner. Selection of data and aspects to focus on more closely were 
primarily at the author’s discretion, which impairs objectivity and may even result in 
omission of significant material. Furthermore, hardly using secondary/tertiary sources 
such as news articles and reputable blogs may have left out valuable interpretations or 
sides of a story. Despite improved reliability when using an original data source instead 
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of another author’s understanding and presentation of that same data, popular 
publications may significantly shape public views and opinions, which makes them 
meaningful. As the so-called “Thomas theorem” states, “If men define situations as 
real, they are real in their consequences”.  
 
For future research—closer to the possible market entry—a comprehensive feasibility 
study on England/UK market entry, including necessary technological detail, might be 
of great benefit for Medieta. In addition, Medieta would benefit from a study using 
actual financial data, aiming at quantifying the savings attained by the NHS when using 
Medieta’s device compared to existing practices. Being able to prove this in addition to 
functionality and accuracy would facilitate market entry and contribute to receiving a 
NICE recommendation for the use of the product within the NHS.  
  
37 
 
 
9 Conclusions 
 
A number of demographic trends and the immense pressures already experienced by 
the public health services in England would support there being current and future 
demand for Medieta’s early risk recognition system. The device could provide better 
monitoring for a variety of patients—especially the kind who might not otherwise be as 
comprehensively monitored—which would allow for earlier detection of health status 
deterioration. This would allow a shift of focus towards preventive and more timely 
delivery of care, which would ideally contribute to increased quality of care, more 
informed and earlier discharging of patients, and decreased need for emergency and 
intensive care services.  
 
Nevertheless, entry into public healthcare and purchase by the NHS may not be 
considered certain even if the clinical efficacy of the device can be proven. The costs in 
relation to the benefits must be considered acceptable as well and failure to do so 
would inhibit obtaining an important recommendation from NICE. Furthermore, 
improving efficiency and realising savings is even more important at a time when 
government expenditure on public healthcare is rather flat and a number of NHS trusts 
and foundation trusts are struggling with their finances.  
 
To sum up, if the device can be comprehensively shown to benefit patients at an 
acceptable cost, it would be fair to assume the public healthcare sector in England is a 
suitable new market with sufficient demand, and the device could be purchased by the 
NHS. 
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Appendix 1 
1 (1) 
 
 
Selected quality of care indicators in the UK and four other EU 
countries  
 
Variable Year United Kingdom 
EU 
average Germany France Italy Spain 
Infant mortality (deaths of children 
<1 year of age per 1,000 live 
births) 
2012* 4.1 a 4.0 b 3.3 3.5 2.9 3.1 
Asthma hospital admissions (adults; 
age-sex standardised rates per 
100,000 population) 
2011* 61 51 c 20 37 11 40 
Chronic obstructive pulmonary 
disease (COPD) hospital admissions 
(adults; age-sex standardised rates 
per 100,000 population) 
2011* 227 199 c 212 102 90 211 
Case-fatality within 30 days after 
admission for acute myocardial 
infarction (AMI) in adults aged 45 
and over (admission based; age-
sex standardised rates per 100 
admissions) 
2011* 7.8 7.8 d 8.9 6.2 5.8 8.5 
Case-fatality within 30 days after 
admission for ischemic stroke in 
adults aged 45 and over; age-sex 
standardised rates per 100 
admissions) 
2011* 10.4 9.6 e 6.7 8.5 6.5 10.2 
Cervical cancer, five-year relative 
survival (%) 
2007-
12** 60.9 62.4
 f 64.5 n/a n/a n/a 
Breast cancer, five-year relative 
survival (%) 
2007-
12** 
82.0 82.9 f 85.0 n/a n/a n/a 
Colorectal cancer, five-year relative 
survival (%) 
2007-
12** 54.5 58.5
 f 64.3 n/a n/a n/a 
* or nearest year; ** or nearest period  
a England: 4.0 (ONS, 2014h); b EU28; c EU21; d EU21/12; e EU20/11; f EU15 
 
(OECD, 2014a: 30–31, 86–101) 
 
  
